Best of ASCO - 2014 Annual Meeting

 

Welcome

Immunoconjugates

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers.

Bob T. Li

2502

A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies.

Amir Tahmasb Fathi

TPS2603

A phase 1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors.

Marc S. Ernstoff

TPS2604

CD205-Shuttle study: A first-in-human trial of MEN1309/OBT076 an ADC targeting CD205 in solid tumor and NHL.

Elena Garralda

TPS2606

First-in-human phase 1 study of DS-1062a in patients (pts) with advanced solid tumors (AST).

Jacob M. Sands

TPS2605

HDP-101: Preclinical evaluation of a novel anti-BCMA antibody drug conjugates in multiple myeloma.

Andreas Pahl

e14527

Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.

Erika Paige Hamilton

2546

Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies.

Alex A. Adjei

TPS2607

Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.

Hiroji Iwata

2501